Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ITOS |
---|---|---|
09:32 ET | 4520 | 10.5 |
09:38 ET | 250 | 10.52 |
09:39 ET | 300 | 10.6 |
09:41 ET | 700 | 10.65 |
09:43 ET | 1100 | 10.69 |
09:45 ET | 2500 | 10.75 |
09:48 ET | 200 | 10.83 |
09:50 ET | 200 | 10.805 |
09:52 ET | 506 | 10.81 |
09:54 ET | 1796 | 10.8501 |
09:56 ET | 4791 | 10.895 |
09:57 ET | 100 | 10.93 |
09:59 ET | 2975 | 10.885 |
10:01 ET | 1401 | 10.9 |
10:03 ET | 2499 | 10.9061 |
10:06 ET | 1005 | 10.875 |
10:08 ET | 2000 | 10.895 |
10:10 ET | 910 | 10.92 |
10:12 ET | 1949 | 10.845 |
10:14 ET | 25859 | 10.69 |
10:15 ET | 7728 | 10.72 |
10:17 ET | 1300 | 10.705 |
10:19 ET | 1384 | 10.715 |
10:21 ET | 25357 | 10.5 |
10:24 ET | 100 | 10.495 |
10:26 ET | 300 | 10.49 |
10:28 ET | 9788 | 10.3849 |
10:30 ET | 2967 | 10.48 |
10:32 ET | 700 | 10.45 |
10:35 ET | 2236 | 10.41 |
10:37 ET | 100 | 10.44 |
10:39 ET | 1000 | 10.38 |
10:42 ET | 536 | 10.4 |
10:44 ET | 932 | 10.38 |
10:46 ET | 600 | 10.37 |
10:48 ET | 796 | 10.37 |
10:50 ET | 1845 | 10.29 |
10:51 ET | 200 | 10.32 |
10:53 ET | 1216 | 10.28 |
10:55 ET | 3639 | 10.19 |
10:57 ET | 2027 | 10.16 |
11:00 ET | 400 | 10.17 |
11:02 ET | 819 | 10.16 |
11:04 ET | 300 | 10.18 |
11:06 ET | 799 | 10.27 |
11:08 ET | 505 | 10.23 |
11:09 ET | 2606 | 10.142 |
11:11 ET | 3320 | 10.01 |
11:13 ET | 11429 | 9.931 |
11:15 ET | 4770 | 10.0544 |
11:18 ET | 2464 | 9.99 |
11:20 ET | 5321 | 10.01 |
11:22 ET | 650 | 10.005 |
11:24 ET | 11762 | 10.07 |
11:26 ET | 1454 | 10.07 |
11:27 ET | 100 | 10.05 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Iteos Therapeutics Inc | 609.9M | -3.3x | --- |
Applied Therapeutics Inc | 561.6M | -5.6x | --- |
Lexicon Pharmaceuticals Inc | 614.5M | -2.1x | --- |
Allogene Therapeutics Inc | 619.0M | -1.8x | --- |
LENZ Therapeutics Inc | 601.1M | -2.7x | --- |
Alumis Inc | 600.9M | -3.0x | --- |
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $609.9M |
---|---|
Revenue (TTM) | $35.0M |
Shares Outstanding | 36.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-3.00 |
Book Value | $16.05 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 17.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -413.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.